MedTrace Logo

Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine

NCT05371353 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2024-04-17

No results posted yet for this study

Summary

To access the immune persistence of Chinese women aged 9-45 years after receiving quadrivalent HPV vaccine with the immunization schedule of 0, 2 and 6 months.

Conditions

  • HPV Infections
  • Cervical Cancer Stage IIa
  • Vaginal Cancer
  • Genital Wart
  • CIN1
  • CIN2
  • CIN3

Sponsors & Collaborators

  • Shanghai Bovax Biotechnology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Jikai Zhang · Guangdong Center for Disease Prevention and Control

Eligibility

Min Age
9 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-05-14
Primary Completion
2027-05-31
Completion
2027-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05371353 on ClinicalTrials.gov